WASHINGTON (AP) — Pfizer will pay $35 million to resolve allegations by 42 states that its subsidiary, Wyeth Pharmaceuticals, illegally marketed an organ transplant drug for unapproved uses.

The states’ attorneys general said Wednesday that Wyeth, which Pfizer bought in 2009, trained sales representatives to encourage doctors to prescribe Rapamune for uses other than preventing rejection of transplanted kidneys.

Recommended Stories

DOJ insists it just wants Alaska ballots preserved and isn’t seeking to change votes

Hundreds evacuate Ukrainian city of Oleshky as part of Melania Trump-brokered ceasefire

Judge opens inquiry into Trump administration’s handling of East Potomac golf course case